Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo ( (AU:PNV) ) has provided an update.
PolyNovo Limited has appointed Amy Demediuk as Company Secretary and General Counsel, effective February 2026. Ms. Demediuk brings extensive legal and compliance experience from her previous roles at CSL, enhancing PolyNovo’s leadership team as it seeks to continue its growth trajectory. Her appointment is expected to add significant value to the company’s operations and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company is known for its NovoSorb technology, which includes bio-resorbable polymers used in various formats for wound healing. PolyNovo has treated over 84,000 patients across 46 countries and is focused on growth through new products, indications, and markets.
YTD Price Performance: -40.93%
Average Trading Volume: 2,715,789
Technical Sentiment Signal: Sell
Current Market Cap: A$832.5M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.